|
|
 |
 |
 |
|
October 26, 2006
4Discovery Labs Restructures Loan Arrangement
with Quintiles
October
12, 2006 @ 9:00 AM
4Discovery Labs Announces Topline Results of
Surfaxin Phase 2 Clinical Trial for the Prevention and
Treatment of BPD
October 10, 2006
4Surfaxin® Treated Premature infants Require
Fewer Re-intubations Compared with Animal Derived
Surfactants
September 28, 2006
4Discovery Labs Updates Progress on Manufacturing
Remediation and Surfaxin® FDA Regulatory Matters
July
28, 2006
4Discovery Labs Reports Second Quarter 2006
Financial Results
July 26, 2006
4Discovery Labs Announces Second Quarter
Conference Call and Webcast
June 27, 2006
4Discovery Labs Reports Progress on its
Surfactant Manufacturing Remediation
June 21, 2006
4Pulmonary Surfactant Commercial Expert Rejoins
Discovery Labs’ Executive Management Team
June 19, 2006
4Discovery Labs to Present at the Jefferies Life
Sciences Conference
June 15, 2006
4Discovery Labs’ Surfaxin® Granted Orphan Drug
Designation for the Prevention of Bronchopulmonary
Dysplasia
June 7, 2006
4Discovery Labs Withdraws European Marketing
Application for Surfaxin®
May
10, 2006
4Discovery Labs Reports First Quarter 2006
Financial Results
May
10, 2006
4Discovery Labs Announces First Quarter
Conference Call and Webcast
May 5, 2006
4Discovery Labs Announces Corporate
Reorganization and Personnel Reduction
April 25, 2006
4Discovery Labs Reports Surfaxin Manufaturing
Issue
April
25, 2006
4Discovery Labs Provides Business and Financial
Update
April
19, 2006
4Discovery Labs
Secures $50 Million Committed Equity Financing Facility
April 12, 2006
4Discovery Labs Provides Update on Surfaxin
Regulatory Progress
April 5, 2006
4Discovery Labs Receives Second Approvable Letter
from FDA for Surfaxin for RDS
March
31, 2006
4Discovery Labs Announces Preliminary Results of
Phase 2 Clinical Trial in ARDS
March
7, 2006
4Discovery Labs Presents at the SG Cowen Health
Care Conference
February
24, 2006
4Discovery Labs Grants 10 Neonatology Fellowship
Awards
February
24, 2006
4Discovery Labs Reports Fourth Quarter 2005
Financial Results and Business Progress
February
15, 2006
4Discovery Labs to Present at the BIO CEO &
Investor Conference
February 6, 2006
4Discovery Labs Adds Senior Medical and Clinical
Executives with Broad Pulmonology Expertise
February
1, 2006
4Discovery Labs to Present at the Brean Murray,
Carret & Co. Conference
January
26, 2006
4FDA Grants Discovery Labs’ Surfaxin® Fast Track
Designation for Prevention and Treatment of
Bronchopulmonary Dysplasia
January
12, 2006
4Discovery Labs to Present at the JP Morgan
Healthcare Conference
December
28, 2005
4Discovery Labs’ Broadens Management Team - Hires
Senior Manufacturing and Quality Executives
December
28, 2005
4Discovery Labs to Acquire Laureate Pharma’s
Manufacturing Operation in Totowa, N.J.
December
20, 2005
4Discovery Labs Announces Completion of $20.0
Million in Registered Direct Offering
December
14, 2005
4Discovery Labs to Raise $20.0 Million in
Registered Direct Offering
December
11, 2005
4Discovery Labs Forms a Strategic Alliance with
Chrysalis Technologies to Develop Aerosolized SRT for
Respiratory Diseases
December
7, 2005
4Discovery Labs to Present at the First Albany
Capital Conference
November
3, 2005
4Discovery Labs' Reports Third Quarter Earnings
and Business Progress
October
28, 2005
4Discovery Labs' Surfaxin Granted Orphan Drug
Designation for the Treatment of Bronchopulmonary
Dysplasia
October
21, 2005
4FDA Accepts Discovery Labs' Complete Response to
Approvable Letter for Surfaxin
October
20, 2005
4Discovery Labs' Surfaxin Licensed in Italy by
Dompe Farmaceutici
October
11, 2005
4Discovery Labs Files Universal Shelf
Registration Statement
September
20, 2005
4Discovery Labs to Present at the UBS Global Life
Sciences Conference
September
8, 2005
4Discovery Labs Completes Pilot Phase 2 Study of
Investigational Drug Aerosurf, its Aerosolized
Surfactant Delivered via Nasal CPAP
September1, 2005
4New Health Economic Data Shows Cost Benefit in
using Surfaxin in RDS Babies
August
19, 2005
4Discovery Labs Provides Update on Status of
Response to FDA Approvable Letter for Surfaxin
August
18, 2005
4Discovery Labs Announces Conference Call and
Webcast
August 15, 2005
4Discovery Labs Provides Status of Previously
Submitted Response to FDA Approvable Letter for Surfaxin
August 9, 2005
4Discovery Labs Selected as Founding Member of
the NASDAQ Health Care Index
August
2, 2005
4Discovery Labs Reports Second Quarter
2005 Financial Results and Business Progress
July 29, 2005
4Discovery Labs Submits Response to FDA
Approvable Letter for Surfaxin for RDS in Premature
Infants
July
26, 2005
4Discovery Labs Announces Second Quarter
Conference Call and Webcast
June
6, 2005
4Discovery Labs to Present at the 2005 Pacific
Growth Life Sciences Conference
May
25, 2005
4Discovery Labs to Present at the Needham &
Company Fourth Annual Biotechnology Conference
May 18, 2005
4New Data Shows Surfaxin Survival Benefit
Continues Through One Year of Life
April
27, 2005
4Discovery Labs Reports First Quarter 2005
Financial Results and Business Progress
April 27, 2005
4Discovery Labs Announces First Quarter
Conference Call and Webcast
April 4, 2005
4Discovery
Labs’ Surfaxin (lucinactant) Phase 3 Results Published
in Pediatrics, the Official Journal of the American
Academy of Pediatrics
March 16, 2005
4Discovery Presentation at the SG Cowen
Conference
March 15, 2005
4Discovery
Labs Reports Fourth Quarter 2004 Financial Results and
Business Progress
March 10, 2005
4Discovery
Labs Announces Fourth Quarter Conference Call and Webcast
March 9, 2005
4Discovery
Labs to Present at the SG Cowen 25th Annual Health Care
Conference
February
25, 2005
4Discovery
Labs Announces Completion of $29.1 Million Registered
Direct Offering
February 23, 2005
4Discovery
Presentation at the Bio CEO & Investor Conference
February
21, 2005
4Discovery
Labs to Present at the Bio CEO & Investor Conference
February
18, 2005
4Discovery Labs to Raise Additional $2.6 Million in
Registered Direct Offering
February
18, 2005
4Discovery Labs to Raise $26.5 Million in
Registered Direct Offering
February 14, 2005
4Discovery Labs Update
February
14, 2005
4Discovery Labs Receives Approvable Letter from FDA for
Surfaxin® for
Respiratory Distress Syndrome in Premature Infants
February 2, 2005
4Discovery Labs at Brean Murray & Co., Inc. Institutional Investor Conference
February 1, 2005
4Discovery Labs Provides Update on FDA Review of Surfaxin
NDA
February
1, 2005
4Discovery Labs
Provides Update on FDA Pre-Approval Inspection
Activities Pertaining to Surfaxin® NDA Status
January
6, 2005
4Discovery Labs Initiates Two Phase 2 Clinical
Trials - Surfaxin® for Bronchopulmonary Dysplasia and
Aerosolized SRT to Treat Neonatal Respiratory Failures
|
|
|
|
|
Discovery
Laboratories, Inc. occasionally receives attention from
the media in the form of television and news coverage
and newspaper and magazine articles. This information is
being provided to you on a information basis only. The
information contained in these presentations was current
as of the dates listed and reflected management’s views
as of those dates. The presentations contain certain
forward-looking information that involve inherent risks
and uncertainties, known and unknown, that could cause
outcomes and results to differ materially from those
expressed or implied by such statements. We undertake no
obligation to publicly update any information in the
presentations, which speak as of their respective dates.
This website may link you to other websites that are not
owned or controlled by Discovery. These links are
provided for your convenience only. These sites are
maintained by entities over which Discovery exercises no
control. Accordingly, Discovery expressly disclaims any
responsibility for the content, the accuracy of the
information and/or quality of products or services
provided by or advertised on these third-party sites. If
you choose to hyperlink to another website, you do so at
your own risk. The press releases and information stored
here shall not constitute an offer to sell or a
solicitation of an offer to buy any securities of the
Company. To the extent that statements in the press
releases and information stored here are not strictly
historical, including statements as to the Company's
business strategy, outlook, objectives, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's
product development, or otherwise as to future events,
such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The
forward-looking statements contained in these releases
are subject to certain risks and uncertainties that
could cause actual results to differ materially from the
statements made. Among the factors which could affect
the Company's actual results and could cause results to
differ from those contained in the forward-looking
statements contained herein are the risk that financial
conditions may change, the risk that the Company will
not be able to raise additional capital or enter into
additional collaboration agreements, risks relating to
the progress of the Company's research and development
and the development of competing therapies and/or
technologies by other companies. Those associated risks
and others are further described in the Company's
periodic filings with the Securities and Exchange
Commission, including the most recent reports on Forms
10-KSB, 8-K, 10-QSB and 10-Q, and amendments thereto.
|
|
|
|